Literature DB >> 7244243

Hepatic artery embolization in the treatment of hepatic neoplasms.

V P Chuang, S Wallace.   

Abstract

Seventy-two hepatic artery embolizations were performed in 47 patients to treat hepatic neoplasms. Hepatic artery embolization creates tumor devascularization, but the portal flow prevents infarction of liver parenchyma because of the single vascular supply from the hepatic artery to a neoplasm, in contrast to the dual vascular supply to the liver parenchyma. Indications for the use of hepatic artery embolization are failure of chemotherapy, either systemic or intra-arterial infusion, vascular anomalies requiring combined lobar embolization and lobar infusion, and lack of effective treatment. Three types of embolization were performed: peripheral embolization using Gelfoam, proximal embolization using coils, and combined peripheral and proximal embolization. The complications after embolization were pain, fever, and transient liver function changes. No death or hepatic abscess occurred. The median survival duration of the group was 11.5 months from the time of embolization. Hepatic artery embolization is an effective treatment of hepatic neoplasm.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7244243     DOI: 10.1148/radiology.140.1.7244243

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  55 in total

1.  Analysis of prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization.

Authors:  K Yamamoto; M Masuzawa; M Kato; T Okuyama; K Tamura
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Effect of arterial administration of a high molecular weight anti-tumor agent, styrene maleic acid neocarzinostatin, for multiple small liver cancer--a pilot study.

Authors:  K Ikeda; S Saitoh; Y Suzuki; A Tsubota; I Koida; M Kobayashi; Y Arase; K Chayama; N Murashima; H Kumada
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

Review 3.  Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions.

Authors:  Meaghan S Dendy; Johannes M Ludwig; Stacey M Stein; Hyun S Kim
Journal:  Liver Cancer       Date:  2019-01-16       Impact factor: 11.740

Review 4.  Arterial embolization in the management of liver metastases.

Authors:  D J Allison; A Booth
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

5.  Scanning electron microscopy of intrahepatic microvasculature casts following experimental hepatic artery embolization.

Authors:  H Demachi; O Matsui; T Takashima
Journal:  Cardiovasc Intervent Radiol       Date:  1991 May-Jun       Impact factor: 2.740

6.  Radiology-important advances in clinical medicine: vascular occlusive therapy.

Authors:  M Mehringer
Journal:  West J Med       Date:  1983-07

7.  Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report.

Authors:  C C Case; K Wirfel; R Vassilopoulou-Sellin
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

8.  Transcatheter arterial chemoembolization with anticancer drug in iodized oil for primary hepatic carcinoma.

Authors:  J Y Guo; D Yen; Z Z Huang; G D Hu; P C Liu
Journal:  Cardiovasc Intervent Radiol       Date:  1989 Jul-Aug       Impact factor: 2.740

9.  Study of repeated arterial infusion chemotherapy with a subcutaneously implanted reservoir for advanced hepatocellular carcinoma.

Authors:  A Minoyama; M Yoshikawa; M Ebara; H Saisho; N Sugiura; M Ohto
Journal:  J Gastroenterol       Date:  1995-06       Impact factor: 7.527

Review 10.  Living donor liver transplantation in a patient with giant hepatic hemangioma complicated by Kasabach-Merritt syndrome: report of a case.

Authors:  Makoto Meguro; Yuji Soejima; Akinobu Taketomi; Toru Ikegami; Yo-Ichi Yamashita; Noboru Harada; Shinji Itoh; Koichi Hirata; Yoshihiko Maehara
Journal:  Surg Today       Date:  2008-04-30       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.